RestoreVision
Biotech · Tokyo, JP
Sviluppa RV-001, terapia genica optogenetica (rodopsina chimerica via AAV) per ripristinare la vista nelle malattie retiniche.
Funding history
| Date | Round | Amount |
|---|
| Apr 2026 | Bridge RestoreVision raised 1.3 billion yen in a pre-Series B via J-KISS, with Astellas Venture Management, Ajinomoto and Shionogi joining. | $8.4M |
Investors
AjinomotoAstellas Venture ManagementHigin CapitalJIC Venture Growth InvestmentsJapan Science and Technology AgencyKyoto University Innovation CapitalNippon Venture CapitalRemiges VenturesShionogi
Similar companies in Biotech
Explore funding flow on EquityFlow →